Publications

2024

QL325 CLEC12A x CD3

Phase 1 interim results presented at EHA 2024 by our China partner Qilu Pharmaceutical.

A Phase 1, Dose-escalation Study of QLF32101, a CLL1/CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Acute Myeloid Leukemia

QL301 PD-L1 x 4-1BB

Phase 1 results presented at ASCO 2024 by our China partner Qilu Pharmaceutical.

A Phase 1, Dose Escalation/Dose-expansion Study of QLF31907, a Bispecific Antibody Targeting PD-L1 and 4-1BB, in Patients with Advanced Solid Tumors and Lymphoma

QL335 LY6G6D x CD3

Preclinical data presented at AACR 2024.

QL335, a novel T cell engager with enhanced safety profile targeting MSS colorectal cancer with Advanced Solid Tumors and Lymphoma

QL325 CLEC12A x CD3

Preclinical data presented at AACR 2024.

Preclinical development of QL325, a novel T cell engager targeting CLEC12A-positive AML

2023

QL401 PD-L1 x CD47

Research paper published in the journal Frontiers in Drug Discovery.

Generation of a potent anti-PD-L1-CD47 bispecific antibody with a strong therapeutic and safety profile for cancer immunotherapy

2022

QL301 PD-L1 x 4-1BB

Preclinical data presented at AACR 2022.

QL301, a PD-L1 dependent 4-1BB agonist with enhanced preclinical anti-tumor efficacy and minimal liver toxicity

QL401 PD-L1 x CD47

Preclinical data presented at AACR 2022.

QL401, a dual PD-L1 / CD47 blocker effective against both solid and hematological malignancies with improved blood safety

QL415 PD-L1 x IL-15

Preclinical data presented at AACR 2022.

QL415, a tumor targeted IL-15 fusion protein stimulating both lymphoid and myeloid immune cells for optimal anti-tumor immune response

2020

QL315 LRRC15 x CD3

Preclinical data presented at AACR 2020.

QL315, A CD3 Bispecific Antibody Redirecting T cell Activation to Tumor Stroma Antigen LRRC15